Hologic (NASDAQ:HOLX) Price Target Increased to $91.00 by Analysts at JPMorgan Chase & Co.

Hologic (NASDAQ:HOLX) had its target price increased by analysts at JPMorgan Chase & Co. from $85.00 to $91.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 18.89% from the stock’s current price.

HOLX has been the topic of several other research reports. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their target price for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, Raymond James increased their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $84.56.

Hologic Trading Up 0.8 %

NASDAQ:HOLX traded up $0.63 on Friday, hitting $76.54. 2,069,424 shares of the stock were exchanged, compared to its average volume of 1,449,410. The stock has a fifty day moving average of $76.13 and a 200-day moving average of $73.05. The stock has a market cap of $17.97 billion, a PE ratio of 39.05, a PEG ratio of 2.59 and a beta of 1.01. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. Hologic has a fifty-two week low of $64.02 and a fifty-two week high of $86.74.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.81%. The company’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 EPS. As a group, equities analysts expect that Hologic will post 4.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by insiders.

Institutional Trading of Hologic

Institutional investors and hedge funds have recently modified their holdings of the business. SPC Financial Inc. acquired a new stake in Hologic during the first quarter worth about $1,005,000. Mediolanum International Funds Ltd bought a new position in shares of Hologic during the first quarter valued at approximately $1,793,000. Chevy Chase Trust Holdings LLC raised its position in shares of Hologic by 3.7% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 168,375 shares of the medical equipment provider’s stock worth $13,127,000 after purchasing an additional 6,077 shares during the period. Central Pacific Bank Trust Division bought a new stake in shares of Hologic in the 1st quarter worth approximately $77,000. Finally, Jennison Associates LLC boosted its position in Hologic by 13.6% during the 1st quarter. Jennison Associates LLC now owns 478,101 shares of the medical equipment provider’s stock valued at $37,273,000 after purchasing an additional 57,120 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.